Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma

Jeffrey S. Weber, MD, PhD
Published: Wednesday, Nov 08, 2017



Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab (Opdivo) versus ipilimumab (Yervoy) for patients with melanoma.

Most physicians who work with PD-1 antibodies would agree that they are well tolerated, states Weber. Less than 10% of patients treated with nivolumab need to stop treatment due to side effects whereas more than 40% of patients with ipilimumab stopped treatment due to toxicity.

It is important for treatments in the adjuvant setting to have fewer toxicities, states Weber.



Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab (Opdivo) versus ipilimumab (Yervoy) for patients with melanoma.

Most physicians who work with PD-1 antibodies would agree that they are well tolerated, states Weber. Less than 10% of patients treated with nivolumab need to stop treatment due to side effects whereas more than 40% of patients with ipilimumab stopped treatment due to toxicity.

It is important for treatments in the adjuvant setting to have fewer toxicities, states Weber.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x